Delfi Diagnostics vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Delfi Diagnostics has raised $332M total to develop blood-based cancer detection using whole-genome cfDNA fragmentation analysis and ML; clinically validated FirstLook Lung test; partnering with Hackensack Meridian Health in 2025;
About
Delfi Diagnostics is a biotechnology company founded in 2019 by Victor Velculescu and headquartered in Baltimore, Maryland, specializing in blood-based cancer detection using machine learning and whole-genome sequencing of cell-free DNA (cfDNA). The company''s AI platform analyzes genome-wide fragmentation patterns of cell-free DNA from a simple blood draw — a liquid biopsy — to detect cancer-associated signals across multiple cancer types. This approach, called DELFI (DNA Evaluation of Fragments for Early Interception), generates a large number of features across the entire genome that machine learning models synthesize into a cancer risk score.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
AI Visibility Head-to-Head
Key Details
Also Compare
Delfi Diagnostics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.